In PCa, Graça et al. [27] showed that hydralazine decreases DNMT1 and also DNMT3A/3B mRNA expression, decreases DNMT1 protein levels, restores AR and p21 expression and inhibits the Epidermal Growth Factor Receptor (EGFR) bypass signaling pathway [27]. The gene discussed is DNMT1; the disease is posterior cortical atrophy.